Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-01-07

Clinical Trial Update: Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating azacitidine after allogeneic stem cell transplantation for chronic myeloid leukemia has been completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • AZACITIDINE (AZACITIDINE)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Stem Cell Transplantation, Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2021-01-07